Previous studies have shown that intravitreal delivery of conbercept inhibits angiogenesis in an oxygen-induced retinopathy (OIR) of prematurity model and promotes recovery of edemas in a laser damage model of CNV.28–30 A recent 1-year retrospective clinical study compared conbercept with another anti-VEGF drug in AMD patients with CNV. The gene discussed is VEGFA; the disease is age-related macular degeneration.